skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi 5I,

Looking for a couple stocks in this sector to add to my PBH and ATD holdings. Ideally I would like companies with good Dividend Growth and reasonable valuations. I was looking at MRU, L, and MFI, or any others you may have thoughts on.

Thx,
Chris M.
Read Answer Asked by Christopher on February 10, 2020
Q: For members who want to see short interest, the website https://ceo.ca/ displays it. Search by ticker or just add the ticker to the URL, e.g. https://ceo.ca/LSPD. The current short interest is shown upper left and if it is up or down from last report. A two-year short interest history is available by clicking on the current number or the short history icon. Their number for LSPD matches the one you provided in your answer to Bruce earlier today. I assume the 1.1% short in your answer is percentage of the float, not total share count. This site shows only total share count.
Read Answer Asked by David on February 10, 2020
Q: Recent XYL results and the stock drops 7%. I've held for years and it has been one of my more volatile and poorer performing stocks. Yet even after today's action I'm up 15%.

I really want to own XYL largely b/c I firmly believe we'll need more 'engineered' water solutions. However, I'm ready to sell and try something different.

Please tell me why I should continue to hold XYL and not sell to buy WAT, AWK, DHR or and ETF like PHO.

Thx.
Read Answer Asked by Cameron on February 10, 2020
Q: Aside from the obvious demographic appeal of increasing demand for Savaria's products for aging persons with disabilities, it strikes me that as seniors have increasing need for cash flow in later years, they will turn more and more to reverse mortgages. This will lock them in as long as they can live in the financed home. That said, faced with disabilities that might otherwise force them to leave their home, purchasing Savaria's products will be the only solution. Do you agree? Do analysts understand this market force?
Read Answer Asked by Geoffrey on February 10, 2020
Q: Hi Team,
I know that 5I prefers LHX over LMT. Which has a better growth profile between RTN and LHX and which would you choose. I thank you in advance. Sam
Read Answer Asked by sam on February 09, 2020
Q: Is there any substance to rumors of conversion to corporations? issuing 'free' shares?
Read Answer Asked by OREST on February 09, 2020
Q: Hi,

At what price should one start a position in KL? Under $50?
It has lost about $4 this week since the approved DG takeover announcement.
From prior Q&A, this is one of your top gold picks.
When do you anticipate that KL's management teams will be able to improve performance at DG and that it will start to be reflective in the SP? 6-9 months seem right?

Cheers,
Steve
Read Answer Asked by Stephen on February 09, 2020
Q: Hi Team!

When does GC next report and what is expected vs prior quarter ie Q4 2018 vs Q4 2019. Also can you supply the same numbers for fiscal year 2018 vs expected 2019?
From the charts, they have basically been in a downtrend since March 2019 and leveling off around the $40 mark the last 3-6 months. I have read prior Q&A and it seems like they may not get back to an upswing until 2021...also supported by your Company page Financials wrt Fy1 12/19 vs Fy2 12/20 EPS numbers.
Can I interpret from this that this may be dead money until then and perhaps it may be better to invest in a company that offers a better upwards trajectory and revisit this stock at a later time? Or should one look further ahead and accumulate at these low prices anticipating better returns as they finish up some projects?
They do seem to have some pretty impressive financial numbers (ROE) and past growth numbers (from your Companies page). Not sure if these have changed given 2019 performance, or lack thereof.
I have held this stock for about 1.5 years.

Cheers,
Steve (in Ottawa)
Read Answer Asked by Stephen on February 09, 2020
Q: In your Feb 7 response to Jerry on PRN after referring to recent strong momentum you say “markets obviously think there is potential here, but the company now needs to start delivering on that potential.”

I would argue that PRN started delivering on the potential long ago – the company received FDA approval Aug 2019 after a successful clinical trial; PRN successfully listed on NASDAQ last fall; the company announced in early January this year a deal and partnership with RadNet, the largest network of outpatient imaging centres in the US; and recently PRN raised US$ 40 million in an equity financing and retired all bank debt ahead of schedule. PRN is now well positioned to scale the business without further dilution.

I recognize there remains commercialization risk and there is reimbursement risk and revenues are essentially non-existent at this early stage but what we have here is a very experienced very competent management team that has done it before with NOVADAQ. Significantly, the CEO Arun and his team are not doing this because they need to money. They will not rush it they will do it right. I think you have mentioned in the past that this is one of the best small cap situations to invest in – assuming you can deal with the volatility and risk.
Read Answer Asked by James on February 09, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!